- Home
- WDI vs CVAC Comparison
WDI vs CVAC Comparison
Compare WDI & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- CVAC
- Stock Information
- Founded
- WDI 2021
- CVAC 2000
- Country
- WDI United States
- CVAC Germany
- Employees
- WDI N/A
- CVAC N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- CVAC Health Care
- Exchange
- WDI Nasdaq
- CVAC Nasdaq
- Market Cap
- WDI 753.0M
- CVAC 764.4M
- IPO Year
- WDI N/A
- CVAC 2020
- Fundamental
- Price
- WDI $14.81
- CVAC $5.40
- Analyst Decision
- WDI
- CVAC Hold
- Analyst Count
- WDI 0
- CVAC 3
- Target Price
- WDI N/A
- CVAC $6.83
- AVG Volume (30 Days)
- WDI 192.6K
- CVAC 2.1M
- Earning Date
- WDI 01-01-0001
- CVAC 08-14-2025
- Dividend Yield
- WDI 11.80%
- CVAC N/A
- EPS Growth
- WDI N/A
- CVAC N/A
- EPS
- WDI 1.12
- CVAC 0.87
- Revenue
- WDI N/A
- CVAC $566,039,775.00
- Revenue This Year
- WDI N/A
- CVAC N/A
- Revenue Next Year
- WDI N/A
- CVAC $24.04
- P/E Ratio
- WDI $12.82
- CVAC $6.24
- Revenue Growth
- WDI N/A
- CVAC 787.60
- 52 Week Low
- WDI $12.16
- CVAC $2.37
- 52 Week High
- WDI $14.69
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- WDI 53.77
- CVAC 65.68
- Support Level
- WDI $14.53
- CVAC $5.30
- Resistance Level
- WDI $14.75
- CVAC $5.58
- Average True Range (ATR)
- WDI 0.11
- CVAC 0.15
- MACD
- WDI -0.04
- CVAC 0.00
- Stochastic Oscillator
- WDI 47.56
- CVAC 80.66
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.